Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies

American Heart Journal

Volumn 164, Issue 2, 2012, Pages 186-193

  Madigan, David ^a   Sigelman, Daniel W ^b   Mayer, James W ^c   Furberg, Curt D ^d   Avorn, Jerry ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b University of New Mexico ^*

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROFECOXIB;

ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; DRUG FATALITY; DRUG WITHDRAWAL; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LACTONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONES; THROMBOSIS;

EID: 84864655722     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.05.002     Document Type: Article

References (53)

1. R.S. Bresalier, R.S. Sandler, and H. Quan Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102 (Pubitemid 40365350)
2. R.V. Gilmartin Prepared testimony, Raymond V. Gilmartin, president, chairman and chief executive officer, Merck and Co., Inc before the United States Committee on Finance November 18 2004 4 http://finance.senate.gov/imo/ media/doc/111804RGtest.pdf Last accessed June 12, 2012
3. F. Catella-Lawson, B. McAdam, and B.W. Morrison Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 289 1999 735 741 (Pubitemid 29191226)
4. Final Results of an Analysis of the Incidence of Cardiovascular SAEs in the Phase IIb/III VIOXX Osteoarthritis Clinical Trials, February 2, 1998, MRK-NJ0066804 at MRK- NJ0066808.
5. M.R. Weir, R.S. Sperling, and A. Reicin Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program Am Heart J 146 2003 591 604 (Pubitemid 37281702)
6. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
7. 3/23/00 preliminary VIGOR report to FDA, MRK-ABK0460838 at 65, pp. 47-48, http://www.merck.com/newsroom/vioxx/pdf/014-appendix%20-e-mercks- interpretation-of-and-response-to-vigor-trial-cardiovascular-data-march-9-27- 2000.pdf. Last accessed June 12, 2012.
8. P.S. Kim, and A.S. Reicin Rofecoxib, Merck, and the FDA N Engl J Med 351 2004 2875 2876
9. Remarks of Peter S. Kim, Ph.D., President, Merck Research Laboratories, Merck and Co., Inc. at a Press Availability in New York City, October 13, 2004, http://www.drugs.com/news/merck-research-chief-details-background-vioxx- withdrawal-3535.html. Last accessed June 12, 2012.
10. Rofecoxib FDA Advisory Committee Background Information, pp. 33 and 160, http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1-02-MERCK-Vioxx.pdf. Last accessed June 12, 2012.
11. Rofecoxib FDA Advisory Committee Background Information, p. 162-63, http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1-02-MERCK-Vioxx.pdf. Last accessed June 12, 2012.
12. MRKABS146673 at 0146743 (Protocol for 078).
13. MRK-AFS0001987 (Data Analysis Plan for 078).
14. MRK-JAG0002113 (Data Analysis Plan for 091).
15. J.S. Ross, D. Madigan, and K.P. Hill Pooled analysis of rofecoxib placebo-controlled clinical trial data Arch Intern Med 169 2009 1976 1985
16. Merck Statement on Article in The Archives of Internal Medicine Involving VIOXX®, November 23, 2009, http://www.merck.com/newsroom/news-release- archive/corporate/2009-1123b.html. Last accessed June 12, 2012.
17. S.C. Chow Encyclopedia of biopharmaceutical statistics 2nd ed 2003 Informa Healthcare 176
18. L.M. Friedman, C.D. Furberg, and D.L. Demets Fundamentals of clinical trials 4th ed. 2010 Springer Publishing Co New York, NY
19. A.S. Kesselheim, and J. Avorn The role of litigation in defining drug risks JAMA 297 2007 308 311 (Pubitemid 46143310)
20. Rofecoxib FDA Advisory Committee Background Information, p. 75, http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1-02-MERCK-Vioxx.pdf. Last accessed June 12, 2012.
21. D.O. Martin, and H. Austin Exact estimates for a rate ratio Epidemiology 7 1996 29 33 (Pubitemid 26003842)
22. H. Sahai, and A. Khurshid Statistics in epidemiology: methods, techniques, and applications 1996 CRC Press Boca Raton, FL Chapter 10
23. B.M. Psaty, and R.A. Kronmal Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment JAMA 299 2008 1813 1817
24. J.S. Ross, D. Madigan, and M.A. Konstam Persistence of cardiovascular risk after rofecoxib discontinuation Arch Intern Med 170 2010 2035 2036
25. Transcript of Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume I, February 16, 2005, comments of Robert J. Temple, Director of FDA's Office of Medical Policy, pp. 279-80, http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T1.htm. Last accessed June 12, 2012.
26. Transcript of Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume I, February 16, 2005, comments of voting FDA consultant Thomas Fleming, Ph.D., p. 281, http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T1.htm. Last accessed June 12, 2012.
27. J.A. Baron, R.S. Sandler, and R.S. Bresalier Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial Lancet 372 2008 1756 1764
28. S.E. Nissen Adverse cardiovascular effects of rofecoxib N Engl J Med 355 2006 203
29. R.S. Bresalier, and J.A. Baron Adverse cardiovascular effects of rofecoxib N Engl J Med 355 2006 205
30. Council for International Organizations of Medical Sciences (CIOMS). Management of safety information from clinical trials: report of CIOMS Working Group VI. ISBN 92 9036 079 8, Geneva.
31. The Anturane reinfarction trial research group Sulfinpyrazone in the prevention of sudden death after myocardial infarction N Engl J Med 302 1980 250 256
32. R. Temple, and G.W. Pledger The FDA's critique of the Anturane reinfarction trial N Engl J Med 303 2006 1488 1492
33. M.E. Burleigh, V.R. Babaev, and J.A. Oates Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice Circulation 105 2002 1816 1823 (Pubitemid 34408892)
34. D.C. Brater Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition Am J Med 107 1999 65S 70S
35. D.A. Sica, A.C. Schoolwerth, and T.W.B. Gehr COX-2 inhibition: a cautionary note in congestive heart failure Congest Heart Fail 6 2000 272 276 (Pubitemid 32923799)
36. Farquhar JW, Jewell NP. Cardiovascular toxicity of the COX-2 Inhibitor Rofecoxib and its relationship to baseline risk and hypertension. Preprint.
37. Transcript of Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume I, February 16, 2005, comments of FDA medical reviewer Maria Lourdes Villalba, pp. 232 and 247, http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T1.htm. Last accessed June 12, 2012.
38. Merck's December 18, 2001 letter to FDA's Division of Anti-Inflammatory, Analgesic and Ophthalmologic Drug Products, MRK-AAF0005014.
39. Transcript of Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume I, February 16, 2005, comments of Dr. Steven Nissen, p. 188, http://www.fda.gov/ohrms/dockets/ac/05/ transcripts/2005-4090T1.htm. Last accessed June 12, 2012.
40. Transcript of Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume I, February 16, 2005, pp. 278-79, http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T1.htm. Last accessed June 12, 2012.
41. Transcript of Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume I, February 16, 2005, p. 266, http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T1.htm. Last accessed June 12, 2012.
42. Transcript of Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Volume I, February 16, 2005, comments of voting FDA consultant, Ralph B, D'Agostino, Ph.D., p. 291, http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T1.htm. Last accessed June 12, 2012.
43. Clinical Study Report for Study 078, http://dida.library.ucsf.edu/pdf/ oxx17j10. Last accessed June 12, 2012.
44. Clinical Study Reports for Studies 091 and 126, http://dida.library.ucsf. edu/pdf/oxx16n10. Last accessed June 12, 2012.
45. P.C. Gotzsche, and A.W. Jorgensen Opening up data at the European Medicines Agency BMJ 342 2011 d2686
46. W. Rief, J. Avorn, and A.J. Barsky Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects Arch Intern Med 166 2006 155 160 (Pubitemid 43144937)
47. W. Rief, Y. Nestoriuc, and A. von Lilienfeld-Toal Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis Drug Saf 32 2009 1041 1056
48. Rofecoxib FDA Advisory Committee Background Information, p. 124, http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1-02-MERCK-Vioxx.pdf. Last accessed June 12, 2012.
49. L.J. Thal, S.H. Ferris, and L. Kirby Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment Neuropsychopharmacology 30 2005 1204 1215 (Pubitemid 40720980)
50. D.J. Graham, D. Campen, and R. Hui Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet 365 2005 475 481 (Pubitemid 40215729)
51. D.Y. Graham, N.P. Jewell, and F.K.L. Chan Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation Am J Med Sci 342 2011 356 364
52. D. Carpenter Reputation and power: organizational image and pharmaceutical regulation at the FDA 2010 Princeton University Press Princeton, NJ
53. J. Avorn Learning about the safety of drugs: a half-century of evolution N Engl J Med 365 2011 2151 2153